GlassScriptPhysician profile
Krishna Pokala
NPI 1578856399
$143,461.35
in general payments reported to CMS, 2019-2025
28 companies · $45K in 2025
The $45K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $2,251 · 2021: $3,821 · 2022: $22K · 2023: $21K · 2024: $40K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Consulting Fee: $19K · Travel and Lodging: $12K · Food and Beverage: $4,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,478.14 |
| Consulting Fee | $19,162.44 |
| Travel and Lodging | $11,525.50 |
| Food and Beverage | $4,405.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $77,333.25 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Takeda Pharmaceuticals U.S.A., INC. | $41,866.86 | 2020-2025 | Hyqvia, Gammagard Liquid, Gammagard |
| Shire North American Group INC | $9,650.63 | 2019 | |
| Amgen INC. | $8,110.48 | 2019-2025 | Uplizna |
| Janssen Biotech, INC. | $3,477.29 | 2025 | |
| Pfizer INC. | $781.70 | 2023 | |
| Genzyme Corporation | $409.84 | 2019-2024 | |
| Abbvie INC. | $225.25 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $216.00 | 2021 | |
| Amicus Therapeutics, INC. | $215.53 | 2024-2025 | Opfolda, Pombiliti |
| Biogen, INC. | $204.40 | 2019-2024 | Spinraza |
| Alexion Pharmaceuticals, INC. | $180.72 | 2019-2023 | Ultomiris |
| Csl Behring | $152.59 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $129.47 | 2021-2022 | |
| Akcea Therapeutics, INC. | $121.84 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $57.24 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $45.50 | 2019 | |
| Merz North America, INC. | $40.74 | 2019-2020 | |
| Genentech, INC. | $40.21 | 2023 | Evrysdi |
| Biohaven Pharmaceutical Holding Company LTD. | $33.02 | 2022 | |
| Grt US Holding, INC. | $31.50 | 2022 | |
| Ucb, INC. | $28.54 | 2024 | |
| Medtronic, INC. | $23.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.82 | 2019-2021 | |
| Grifols USA, LLC | $17.65 | 2019 | |
| Lundbeck LLC | $16.85 | 2019 | |
| Sarepta Therapeutics, INC. | $14.97 | 2020 | |
| Emd Serono, INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Pokala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.